Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining ...

Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing ...

The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI).

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

Explore Ginkgo Bioworks Holdings stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DNA. Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ginkgo Bioworks (DNA) 7.32% +1.48, Kingsoft ...